WO2009038107A1 - Combined pharmaceutical preparation for treatment of type-2 diabetes - Google Patents

Combined pharmaceutical preparation for treatment of type-2 diabetes Download PDF

Info

Publication number
WO2009038107A1
WO2009038107A1 PCT/JP2008/066809 JP2008066809W WO2009038107A1 WO 2009038107 A1 WO2009038107 A1 WO 2009038107A1 JP 2008066809 W JP2008066809 W JP 2008066809W WO 2009038107 A1 WO2009038107 A1 WO 2009038107A1
Authority
WO
WIPO (PCT)
Prior art keywords
acceptable salt
pharmacologically acceptable
diabetes
type
pharmaceutical preparation
Prior art date
Application number
PCT/JP2008/066809
Other languages
French (fr)
Japanese (ja)
Inventor
Mitsutaka Shimasaki
Naoki Kobayashi
Tatsuro Takei
Original Assignee
Kissei Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2007245437 priority Critical
Priority to JP2007-245437 priority
Application filed by Kissei Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited filed Critical Kissei Pharmaceutical Co., Ltd.
Publication of WO2009038107A1 publication Critical patent/WO2009038107A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Abstract

Disclosed is a pharmaceutical preparation comprising a combination of mitiglinide (which is a substance useful for the treatment of type-2 diabetes) or a pharmacologically acceptable salt thereof and pioglitazone or a pharmacologically acceptable salt thereof. Also disclosed is a combined pharmaceutical preparation in which the therapeutic effect of pioglitazone or a pharmacologically acceptable salt thereof on type-2 diabetes can be enhanced in a patient in whom the blood glucose level cannot be sufficiently controlled by the administration of pioglitazone or the pharmacologically acceptable salt thereof alone, and in which the adverse side effects caused by the components contained therein cannot be increased synergistically. Thus, specifically disclosed is a pharmaceutical preparation for the treatment of type-2 diabetes, which comprises a combination of mitiglinide of the formula (Ia) or a pharmacologically acceptable salt thereof and pioglitazone of the formula (IIa) or a pharmacologically acceptable salt thereof.
PCT/JP2008/066809 2007-09-21 2008-09-18 Combined pharmaceutical preparation for treatment of type-2 diabetes WO2009038107A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2007245437 2007-09-21
JP2007-245437 2007-09-21

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009533167A JPWO2009038107A1 (en) 2007-09-21 2008-09-18 The pharmaceutical combination for treatment of type 2 diabetes

Publications (1)

Publication Number Publication Date
WO2009038107A1 true WO2009038107A1 (en) 2009-03-26

Family

ID=40467917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/066809 WO2009038107A1 (en) 2007-09-21 2008-09-18 Combined pharmaceutical preparation for treatment of type-2 diabetes

Country Status (2)

Country Link
JP (1) JPWO2009038107A1 (en)
WO (1) WO2009038107A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1817347A (en) * 2006-03-10 2006-08-16 北京阜康仁生物制药科技有限公司 Medicinal composition with miglinon and proactidil as active components, and preparing method and use thereof
WO2008026668A1 (en) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Medicinal composition containing insulin resistance improving agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1817347A (en) * 2006-03-10 2006-08-16 北京阜康仁生物制药科技有限公司 Medicinal composition with miglinon and proactidil as active components, and preparing method and use thereof
WO2008026668A1 (en) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Medicinal composition containing insulin resistance improving agent

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EIJI KUDO: "Insulin Chusha kara Mitiglinide eno Kirikae no Kanosei", PHARMA MEDICA, vol. 24, no. 6, 10 June 2006 (2006-06-10), pages 125 - 132 *
MASATOSHI KIKUCHI ET AL.: "Sokkosei·Tanjikan Sayogata Insulin Bunpitsu Sokushin'yaku Mitiglinide to Insulin Teikosei Kaizen'yaku Pioglitazone no Heiyo Ryoho no Yuyosei", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 51, no. 1, 25 April 2008 (2008-04-25), pages S-184 *
MASAZUMI FUJIWARA: "SU-yaku kara Mitiglinide eno Kirikae ni yori HbAlC ga Yui ni Teika shita 2-gata Tonyobyo Shorei no Kento", PROGRESS IN MEDICINE, vol. 28, no. 6, 10 June 2008 (2008-06-10), pages 1541 - 1545 *
RYO MORIKAWA ET AL.: "Tandoku o Gappei shita Michiryo 2-gata Tonyobyo no 1-rei", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 50, no. 3, 30 March 2007 (2007-03-30), pages 224 *
SHOICHI HATAKE ET AL.: "Mitiglinide ni yoru To Fukago no Ketto Koka Sayo ni Taisuru Pioglitazone Choki Toyo no Koka -OLETF Rat o Mochiita Kento", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 51, no. 1, 25 April 2008 (2008-04-25), pages S-285 *
SHOICHI HATAKE ET AL.: "Pioglitazone nite Chiryochu no 2-gata Tonyobyo Kanja ni Okeru Mitiglinide Heiyo Koka no Kento -Teiyoryo SU-yaku Heiyo Koka tono Hikaku", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 49, no. 1, 25 April 2006 (2006-04-25), pages S-129 *

Also Published As

Publication number Publication date
JPWO2009038107A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
TWI406863B (en) Mtor inhibitors and pharmaceutical composition and use thereof
EA201101187A1 (en) Anti-diabetic medicines containing dpp-4 inhibitor (linagliptin) optional in combination with other anti-diabetic means
EP3037095A3 (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
NZ561029A (en) Benzazole dervatives, compositions, and method of use as beta-secretase inhibitors
IL186339D0 (en) Dosage forms of risedronate
SI1808168T1 (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
WO2010151020A3 (en) Fast-dissolving oral film for effectively concealing unpleasant tastes
NZ548872A (en) Indazole derivatives as inhibitors of hormone-sensitive lipases
WO2001056959B1 (en) A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
EP2168962A3 (en) Phenylacetamides and their use as glucokinase modulators
MX2007001650A (en) Substituted phenylacetamides and their use as glucokinase activators.
WO2007014895A3 (en) Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
MX2009005797A (en) Carboxylic acid derivative.
WO2004080401A3 (en) Oral insulin therapies and protocol
WO2007108988A3 (en) Infusion device with pressurizable liquid medicament chamber
WO2008043044A8 (en) Devices and methods for endoluminal gastric restriction tissue manipulation, and drug delivery
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
EP2248519A3 (en) Non-mucoadhesive film dosage forms
NZ556343A (en) Spiroketal derivative and use thereof as diabetic medicine
WO2005020892B1 (en) Pharmaceutical compositions and methods for metabolic modulation
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2010056302A3 (en) Iontophoretic therapeutic agent delivery system
CA2560689A1 (en) Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08831697

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009533167

Country of ref document: JP

ENP Entry into the national phase in:

Ref document number: 2009533167

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08831697

Country of ref document: EP

Kind code of ref document: A1